Clinical Features of Children With MOG-IgG Who Fulfill Criteria of Multiple Sclerosis and Overlapping Disorders


Por: Fonseca, EG, Olivé-Cirera, G, Chen, LW, Paredes-Carmona, F, Enamorado, NN, Duran, SB, Mendibe, MD, Visa-Reñe, N, Vázquez-López, M, Felipe-Rucián, A, Romeu-Cerrillo G, Martinez-Hernandez, E, Blanco, Y, Sepulveda, M, Saiz, A, Dalmau, J and Armangue-Salvador T

Publicada: 1 jul 2025
Resumen:
Objectives The aim of this study was to report the clinical features, disease-modifying treatment (DMT) response, and outcomes of children with MOG-IgG who fulfill the 2017 McDonald criteria for multiple sclerosis (MS). Methods This prospective observational study included children (<18 years) with a suspected acquired demyelinating syndrome (ADS) whose serum or CSF was positive for MOG-IgG, who met the indicated MS criteria, and who had >= 1 year of clinical follow-up. MOG-IgG was tested using live cell-based assays. Results Of 554 children with confirmed ADS (196 with MOG-IgG), 8 (median age 11 years, interquartile range 9-14) harbored MOG-IgG and fulfilled MS criteria: 2 had typical MS and 6 had overlapping MOGAD-MS features at onset, but 5 of the latter group developed an MS-like course during follow-up. Five of 7 patients with assessable samples were Epstein-Barr virus seropositive at disease onset, and all 8 had persistent silent radiologic activity with lesional location and morphology suggestive of MS, leading to initiation of DMT. All initial treatments were well tolerated, but eventually, 7 of 8 children (88%) required high-efficacy DMT. Discussion In this pediatric cohort, 4% of patients with MOG-IgG met criteria for MS. The clinical-radiologic spectrum ranged from typical MS to overlapping MOGAD-MS, and patients usually required high-efficacy DMT.

Filiaciones:
Fonseca, EG:
 Hosp Clin Barcelona, Caixa Res Inst, Inst Invest Biomed August Pi Sunyer IDIBAPS, Neuroimmunol Program, Barcelona, Spain

 Univ Barcelona, Sant Joan Deu Childrens Hosp, ERN RITA reference Ctr, Pediat Neuroimmunol Unit,Neurol Dept, Barcelona, Spain

Olivé-Cirera, G:
 Hosp Clin Barcelona, Caixa Res Inst, Inst Invest Biomed August Pi Sunyer IDIBAPS, Neuroimmunol Program, Barcelona, Spain

 Univ Barcelona, Sant Joan Deu Childrens Hosp, ERN RITA reference Ctr, Pediat Neuroimmunol Unit,Neurol Dept, Barcelona, Spain

 Hosp Santa Creu & Santa Pau, Pediat Neurol Dept, Barcelona, Spain

Chen, LW:
 Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Pediat, Tainan, Taiwan

Paredes-Carmona, F:
 Hosp Arnau Vilanova, Pediat Neurol Sect, Lleida, Spain

Enamorado, NN:
 Hosp 12 Octubre, Pediat Neurol Dept, Madrid, Spain

Duran, SB:
 Hosp Univ Cruces, Biobizkaia Hlth Res Inst, Neurol Dept, Baracaldo, Spain

Mendibe, MD:
 Hosp Univ Cruces, Biobizkaia Hlth Res Inst, Neurol Dept, Baracaldo, Spain

Visa-Reñe, N:
 Hosp Arnau Vilanova, Pediat Neurol Sect, Lleida, Spain

Vázquez-López, M:
 Hosp Gregorio Maranon, Pediat Neurol Dept, Madrid, Spain

Felipe-Rucián, A:
 Hosp Univ Vall dHebron, Pediat Neurol Sect, Barcelona, Spain

Romeu-Cerrillo G:
 Univ Barcelona, Sant Joan Deu Childrens Hosp, Ophtalmol Unit, Barcelona, Spain

Martinez-Hernandez, E:
 Hosp Clin Barcelona, Caixa Res Inst, Inst Invest Biomed August Pi Sunyer IDIBAPS, Neuroimmunol Program, Barcelona, Spain

Blanco, Y:
 Hosp Clin Barcelona, Caixa Res Inst, Inst Invest Biomed August Pi Sunyer IDIBAPS, Neuroimmunol Program, Barcelona, Spain

Sepulveda, M:
 Hosp Clin Barcelona, Caixa Res Inst, Inst Invest Biomed August Pi Sunyer IDIBAPS, Neuroimmunol Program, Barcelona, Spain

Saiz, A:
 Hosp Clin Barcelona, Caixa Res Inst, Inst Invest Biomed August Pi Sunyer IDIBAPS, Neuroimmunol Program, Barcelona, Spain

Dalmau, J:
 Hosp Clin Barcelona, Caixa Res Inst, Inst Invest Biomed August Pi Sunyer IDIBAPS, Neuroimmunol Program, Barcelona, Spain

 Univ Penn, Perelman Sch Med, Dept Neurol, Philadelphia, PA USA

Armangue-Salvador T:
 Hosp Clin Barcelona, Caixa Res Inst, Inst Invest Biomed August Pi Sunyer IDIBAPS, Neuroimmunol Program, Barcelona, Spain

 Univ Barcelona, Sant Joan Deu Childrens Hosp, ERN RITA reference Ctr, Pediat Neuroimmunol Unit,Neurol Dept, Barcelona, Spain

Hosp Clin Barcelona, Caixa Res Inst, Inst Invest Biomed August Pi Sunyer
IDIBAPS, Neuroimmunol Program, Barcelona, Spain
Univ Barcelona, Sant Joan Deu Childrens Hosp, ERN RITA reference Ctr,
Pediat Neuroimmunol Unit,Neurol Dept, Barcelona, Spain
Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Pediat,
Tainan, Taiwan
Hosp Univ Cruces, Biobizkaia Hlth Res Inst, Neurol Dept, Baracaldo,
Spain
Univ Barcelona, Sant Joan Deu Childrens Hosp, Ophtalmol Unit, Barcelona,
ISSN: 23327812





Neurology-Neuroimmunology & Neuroinflammation
Editorial
LIPPINCOTT WILLIAMS & WILKINS, TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103, Estados Unidos America
Tipo de documento: Editorial Material
Volumen: 12 Número: 4
Páginas:
WOS Id: 001525803000001
ID de PubMed: 40505071
imagen Green Submitted, gold

MÉTRICAS